Dmytro Kharkov

Taysha Gene Therapies, Inc. to present TSHA-102 Rett syndrome clinical program at scientific meeting

Taysha Gene Therapies, Inc. to present TSHA-102 Rett syndrome clinical program at scientific meeting
Taysha plans Rett therapy update

Taysha Gene Therapies, Inc. plans to deliver presentations on its TSHA-102 gene therapy program at the 2026 International Rett Syndrome Foundation Scientific Meeting, scheduled for June 29 to July 1, 2026.

The company announced its clinical-stage work on TSHA-102, which is under evaluation for Rett syndrome, will be a key focus at the meeting. This event provides a platform for the latest developments and ongoing research in the field of Rett syndrome and potential therapeutic approaches.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.